Essential thrombocythemia (ET) is a hematological malignancy characterized by thrombocytosis. Based on patients’ age and clinical findings, patients can be classified into different categories, with different therapeutic approaches and prognoses. Most patients respond adequately to first-line treatments, but there is a high unmet need for second-line agents that can be used in patients who do not respond to first-line therapy or cannot tolerate it.

QUESTIONS ANSWERED

  • How are ET patients currently managed? What are the key drivers of and barriers to the uptake of ET therapies? How are the different agents positioned across the major formularies?
  • What is the approximate size of the diagnosed ET population in the United States? What are the key areas of unmet need and opportunity in the treatment of ET?
  • What is the expected impact of novel therapy launches, especially drugs with novel mechanisms of action? How does each current and future player influence the ET therapy market, and how will this scenario change in the future?

PRODUCT DESCRIPTION

Executive Insights provides indication-specific market intelligence with world-class epidemiology, keen insight into current treatment paradigms, biotherapeutic pipelines, key clinical unmet needs, and competitive landscapes, supported by primary and secondary research. This solution provides succinct insights to any biopharma function or business professional looking to quickly grasp a new indication of interest.

Table of contents

  • Executive Insights (US)
    • Essential Thrombocythemia Executive Insights

Author(s): Kanika Ujla

Kanika Ujla is an Analyst for the Infectious, Niche, & Rare Diseases (INRD) team at Decision Resources Group. In this role she supports the team by conducting primary and secondary research across a range of antibacterial and antiviral indications as well as numerous niche and rare diseases. She holds experience in R&D, consulting, business research with healthcare and life sciences companies